Mydocalm (Tolperisone Hydrochloride)

Tolperisone hydrochloride is thought to block voltage‑gated sodium channels on peripheral motor neurons, decreasing neuronal excitability and limiting repetitive firing. This reduces excessive skeletal muscle tone and eases muscle stiffness without strong central nervous system depression.

The dosage of Mydocalm is individualized by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for tolperisone hydrochloride in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and under medical supervision.

To request Mydocalm, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with many centrally acting relaxants such as baclofen or tizanidine, tolperisone has a lower propensity for sedation and does not act directly on the central nervous system. Its primary action is peripheral sodium‑channel blockade, which may result in fewer CNS‑related side effects for some patients.

Mydocalm tablets should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and discard any tablets that appear discoloured or damaged.

Mydocalm is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional. Administration timing (e.g., with meals) is determined by the prescriber.

Serious but rare risks include severe hypotension, allergic reactions such as rash or urticaria, hepatic enzyme elevations, and agranulocytosis. Patients should seek immediate medical attention if they experience signs of an allergic reaction, unexplained dizziness, or signs of infection.

Mydocalm is contraindicated in patients with known hypersensitivity to tolperisone or any excipients in the tablet. Caution is advised for individuals with severe liver impairment, uncontrolled hypotension, or those taking other potent CNS depressants. Pregnant or nursing women should only use it when clearly indicated by a physician.